Canada Markets closed

Orchard Therapeutics plc (ORTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.9900+0.0900 (+3.10%)
At close: 4:00PM EDT
3.0200 +0.03 (1.00%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close2.9000
Bid2.9300 x 800
Ask2.9500 x 900
Day's Range2.8513 - 3.0500
52 Week Range2.7900 - 9.0800
Avg. Volume550,657
Market Cap370.069M
Beta (5Y Monthly)1.15
PE Ratio (TTM)N/A
EPS (TTM)-1.3200
Earnings DateAug. 04, 2021 - Aug. 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.20
  • GlobeNewswire

    Orchard Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Business Updates

    Regulatory feedback obtained on OTL-200 (MLD) and OTL-203 (MPS-IH) programs New HAE collaboration with Pharming Group highlights broad potential for HSC gene therapy Multiple presentations from neurometabolic programs at MPS Symposia including additional follow-up in MPS-IH Cash and Investments of Approximately $270M Provide Runway into First Half 2023 BOSTON and LONDON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today reported financial

  • GlobeNewswire

    Orchard Therapeutics and Pharming Group Announce Collaboration to Develop and Commercialize ex vivo autologous HSC Gene Therapy for Hereditary Angioedema

    Highlights the broader potential of Orchard’s ex vivo HSC gene therapy platform approach in new and larger indications Reinforces Pharming’s commitment to the HAE community and utilizes its relevant clinical expertise and global commercialization infrastructure Companies to host joint investor call at 8:00 a.m. EDT / 2:00 p.m. CEST BOSTON, LONDON and LEIDEN, The Netherlands, July 01, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, and Pharming Group N.

  • GlobeNewswire

    Orchard Therapeutics Announces Regulatory and Clinical Updates for Lead Gene Therapy Programs

    Expected clinical package for OTL-200 BLA for MLD using data from existing patients clarified with FDA Guidance obtained on design of OTL-203 global registrational trial for MPS-IH Enrollment goal met in OTL-201 POC trial for MPS-IIIA Updates for OTL-103 MAA and BLA submission timelines for WAS Company to host conference call today at 8:00 a.m. ET BOSTON and LONDON, June 29, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced several progra